Endocyte's P2P Acquisition

Endocyte raised a round of funding on December 21, 2018. Investors include Novartis.

Endocyte is a biotechnology company developing receptor-targeted therapeutics or "smart drugs" for the treatment of cancer and autoimmune diseases. The Company focuses on certain types of cancer cells…

Articles about Endocyte's P2P Acquisition: